Published in Am J Pathol on February 01, 1993
Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol (2004) 1.24
Characterization of the expanded T cell population in infectious mononucleosis: apoptosis, expression of apoptosis-related genes, and Epstein-Barr virus (EBV) status. Clin Exp Immunol (2000) 0.96
New characterization of infectious mononucleosis and a phenotypic comparison with Hodgkin's disease. Am J Pathol (1995) 0.96
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (1988) 6.38
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med (1988) 2.52
Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation (1985) 2.34
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation (1990) 2.13
Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. J Natl Cancer Inst (1986) 1.69
Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J Immunol (1987) 1.60
Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest (1990) 1.49
Hematopathologic features of Epstein-Barr virus-induced human B-lymphoproliferation in mice with severe combined immunodeficiency. A model of lymphoproliferative diseases in immunocompromised patients. Lab Invest (1991) 1.48
AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol (1991) 1.45
Regulation of human B-cell ontogeny. Blood (1990) 1.42
The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients. Am J Clin Pathol (1989) 1.08
Lymphoproliferative disease in organ transplant recipients. Springer Semin Immunopathol (1991) 1.01
Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats. J Virol (1991) 1.01
Characterization of Epstein-Barr virus-induced lymphoproliferation derived from human peripheral blood mononuclear cells transferred to severe combined immunodeficient mice. Am J Pathol (1990) 0.99
Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. Cancer Res (1991) 0.98
Epstein-Barr virus induced lymphoproliferative tumors in severe combined immunodeficient mice are oligoclonal. Blood (1992) 0.87
LFA-1, LFA-3, and ICAM-1 expression in Burkitt's lymphoma. Lancet (1987) 0.82
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology (1993) 3.42
Immune adherence by the fourth component of complement. Science (1969) 3.34
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Purification and radiolabeling of human C1q. J Immunol (1981) 2.75
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
The classical complement pathway: activation and regulation of the first complement component. Adv Immunol (1985) 2.38
Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med (1976) 2.34
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology (1984) 2.11
Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest (1975) 2.07
Immunologic injury of cultured cells infected with measles virus. I. role of IfG antibody and the alternative complement pathway. J Exp Med (1975) 2.06
Complement associated peptidase activity of guinea pig serum. I. Role of complement components. J Immunol (1967) 1.97
Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell (1989) 1.93
Cytotoxic T-cell response to respiratory syncytial virus in mice. J Virol (1985) 1.92
Human serum lyses RNA tumour viruses. Nature (1975) 1.92
Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum. J Exp Med (1975) 1.86
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med (1998) 1.84
Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J Gen Virol (1987) 1.82
Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. J Immunol (1974) 1.74
Studies of an additional kindred with hereditary deficiency of the second component of human complement (C2) and description of a new method for the quantitation of C2. J Immunol (1968) 1.69
Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A (1987) 1.68
Physicochemical and functional characterization of the C1r subunit of the first complement component. J Immunol (1976) 1.67
Formation and function of a complex of the C3 proactivator with a protein from cobra venom. J Exp Med (1973) 1.63
Complement fixation by rheumatoid factor. J Clin Invest (1975) 1.60
Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry (1981) 1.58
Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J Immunol (1985) 1.58
Mechanism of injury of virus-infected cells by antiviral antibody and complement: participation of IgG, F(ab')2, and the alternative complement pathway. J Exp Med (1976) 1.57
Cell cycle-dependent immune lysis of Moloney virus-transformed lymphocytes: presence of viral antigen, accessibility to antibody, and complement activation. Proc Natl Acad Sci U S A (1971) 1.53
Binding and activation of the first component of human complement by the lipid A region of lipopolysaccharides. J Immunol (1978) 1.53
Serum and cerebral spinal fluid complement and serum autoantibodies in systemic lupus erythematosus. Medicine (Baltimore) (1971) 1.52
Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement. J Immunol (1981) 1.50
Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest (1990) 1.49
Expression of a human cytomegalovirus receptor correlates with infectibility of cells. J Virol (1991) 1.48
Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol (1981) 1.44
Active disassembly of the first complement component, C-1, by C-1 inactivator. J Immunol (1979) 1.44
Glomerular complement components in human glomerulonephritis. J Clin Invest (1974) 1.43
Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells. J Immunol (1980) 1.43
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer (2005) 1.39
Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging (1997) 1.36
Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology (1998) 1.34
Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists. Proc Natl Acad Sci U S A (1984) 1.31
Feline idiopathic cardiomyopathy: a retrospective study of 106 cats (1994-2001). J Feline Med Surg (2003) 1.30
Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein. J Virol (1986) 1.29
The human cytomegalovirus receptor on fibroblasts is a 30-kilodalton membrane protein. J Virol (1990) 1.27
The subunit composition and sedimentation properties of human C1. J Immunol (1977) 1.27
Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J Immunol (1991) 1.27
Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J Biol Chem (1989) 1.26
Inactivation of lysis of oncornaviruses by human serum. Virology (1976) 1.26
A substrate recognition role for the [4Fe-4S]2+ cluster of the DNA repair glycosylase MutY. Biochemistry (1998) 1.25
Identification of types of cells in human peripheral blood that bind C1q. J Immunol (1981) 1.25
Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction. J Exp Med (1997) 1.23
Activation of C1r by proteolytic cleavage. J Immunol (1976) 1.23
Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol (2000) 1.22
Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med (1988) 1.21
Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV-lipoprotein complexes in human serum and complement-dependent viral lysis. J Immunol (1979) 1.20
Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest (1982) 1.20
Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett (2001) 1.20
CR2 ligands modulate human B cell activation. J Immunol (1988) 1.18
The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase. J Immunol (1980) 1.18
Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol (2001) 1.17
Stimulation of a human polymorphonuclear leukocyte oxidative response by the C1q subunit of the first complement component. J Immunol (1982) 1.17
Enzymatic activity of the second component of complement. Biochemistry (1975) 1.15
The lymphocytotoxic reaction: the mechanism of rabbit complement action. J Immunol (1971) 1.15
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer (2004) 1.14
Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J Immunol (1983) 1.13
Isolation and characterization of the proenzyme form of the C1r subunit of the first complement component. J Immunol (1974) 1.13
Demonstration and quantitation of activation of the first component of complement in human serum. J Exp Med (1978) 1.11
Formation and biologic role of polyoma virus-antibody complexes. A critical role for complement. J Exp Med (1974) 1.10
Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc Natl Acad Sci U S A (1993) 1.08
Complement in acute experimental malaria. I. Total hemolytic activity. Mil Med (1966) 1.08
Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol (1999) 1.08
Complement in acute experimental malaria. II. Alterations in the components of complement. Mil Med (1966) 1.08
Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody. J Exp Med (1979) 1.07
Antibody-independent neutralization of vesicular stomatitis virus by human complement. I. Complement requirements. J Immunol (1978) 1.06
Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest (2001) 1.06
Human cytomegalovirus binding to fibroblasts is receptor mediated. J Virol (1989) 1.03
Comparison of human herpesvirus 8 and Epstein-Barr virus seropositivity among children in areas endemic and non-endemic for Kaposi's sarcoma. J Med Virol (2004) 1.02
Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines. Viral Immunol (1997) 1.01
Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats. J Virol (1991) 1.01
Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection. J Virol (1990) 1.00
Complement, viruses, and virus-infected cells. Springer Semin Immunopathol (1983) 1.00
Activation of the complement system. Contemp Top Mol Immunol (1973) 0.99
CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. J Immunol (1988) 0.99
Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions. J Immunol (1986) 0.98
Activation of human complement by human lymphoid cells sensitized with histocompatibility alloantisera. Proc Natl Acad Sci U S A (1973) 0.98
Antibody-independent C1 activation by E. coli. J Immunol (1984) 0.98
Development of an immunochemical test to assess C1 inactivator function in human serum and its use for the diagnosis of hereditary angioedema. Clin Immunol Immunopathol (1980) 0.97
Measurement of sodium ion concentration in the unstirred layer of rat small intestine by polymer Na+-sensitive electrodes. Biochim Biophys Acta (1983) 0.97
Biochemical and antigenic analysis of the Epstein Barr virus/C3d receptor (CR2). J Immunol (1986) 0.96
The structure and function of the third component of human complement--I. The nature and extent of conformational changes accompanying C3 activation. Mol Immunol (1981) 0.96
Direct demonstration and quantitation of the first complement component in human serum. Science (1978) 0.96